Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2020

View Archived Issues

New mouse model of MLL-ENL-driven AML to understand the early stages of leukemogenesis

Discovery of amide-linked benzimidazole-benzoxaborole hybrids for the treatment of onchocerciasis

Caelum initiates phase II study of CAEL-101 in AL amyloidosis

Phase II results for pembrolizumab in patients with advanced rare cancers

miR15a-1 as a new a noninvasive biomarker for asthma

Sepsis study may yield new treatment strategies

Dead cells do tell tales

TET1 gene therapy patented by the Military Medical Institute Academy

How lung tumors seed to brain

Roche synthesizes new TLR7/TLR8/TLR9 antagonists

Medshine Discovery discovers drugs targeting protein cereblon

New geranylgeranyl transferase type 1 inhibitors identified at Bayer

Abbisko Therapeutics identifies new fibroblast growth factor receptor inhibitors

Investigators describe biomarkers of liver injury

Gimsilumab completes phase I study in development of gimsilumab for COVID-19-related ARDS

NGM studies NGM-395 in obese adults and patients with NAFLD

New Chinese phase I study evaluates Ad5-nCoV coronavirus vaccine

Lundbeck discontinues foliglurax program in Parkinson's following phase IIa results

FDA approves new intravenous formulation of Triferic

Lundbeck reports phase IIa results with Lu-AG06466 in Tourette's syndrome

FDA approves Imfinzi as first-line treatment for extensive-stage SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...